Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib

Acta Pharmacologica Sinica

Volumn 32, Issue 3, 2011, Pages 399-407

  Dong, Pei Pei ^a,b   Fang, Zhong Ze ^a,b   Zhang, Yan Yan ^a   Ge, Guang Bo ^a   Mao, Yu Xi ^a,b   Zhu, Liang Liang ^a,b   Qu, Yan Qing ^c   Li, Wei ^a,b   Wang, Li Ming ^c   Liu, Chang Xiao ^d   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

CYP isoform; drug interaction; erlotinib; human liver microsomes; substrate dependent inhibition (or modulation)

Indexed keywords

6BETA HYDROXYTESTOSTERONE; ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; ERLOTINIB; ISOENZYME; NIFEDIPINE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; REACTION TIME; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MICROSOMES, LIVER; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 79952386110     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.218     Document Type: Article

References (48)

1. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-70 (Pubitemid 32963812)
2. Smith J. Erlotinib: Small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther 2005; 27: 1513-34 (Pubitemid 41739489)
3. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32 (Pubitemid 41058344)
4. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: Erlotinib (Tarceva (R)) tablets. Oncologist 2005; 10: 461-6. (Pubitemid 41266326)
5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Onco 2007; 25: 1960-6 (Pubitemid 46972777)
6. Vasey PA, Gore M, Wilson R, Rustin G, Gabra H, Guastalla JP, et al. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers. Br J Cancer 2008; 98 1774-80 (Pubitemid 351748839)
7. Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC et al. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmaco 2009; 63: 1065-71.
8. Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J Benlyazid A, et al. Population pharmacokinetics of erlotinib and its pharma cokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 2009; 45: 2316-23
9. Gridelli C, Rossi A, Malone P, Colantuoni G, Del Gaizo F, Ferrara C, et al. Erlotinib in non-small-cell lung cancer. Expert Opin Pharmacother 2007; 8: 2579-92 (Pubitemid 350031295)
10. Schwiertz V, Bertin C, Henry A, Charpiat B. Number and nature of drug interactions concerning antineoplastic drugs. Bull Cancer 2007 94: 477-82 (Pubitemid 46981011)
11. Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, et al. Phase 1, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res 2006; 12: 7406-13 (Pubitemid 46095415)
12. Grenader T, Gipps M, Shavit L, Gabizon A. Signifcant drug interaction Phenytoin toxicity due to erlotinib. Lung Cancer 2007; 57: 404-6 (Pubitemid 47285413)
13. Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer 2008; 9: 232-34
14. Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 2006; 34: 420-6 (Pubitemid 43290900)
15. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13: 3731-7 (Pubitemid 46955138)
16. Harmsen S, Meijerman I, Beijnen JH, Schellens JHM. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmaco 2009; 64: 35-43
17. Liu Y, Ramirez J, House L, Ratain MJ. Comparison of the drug-drug nteractions potential of erlotinib and geftinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 2010; 38: 32-9
18. Zhang YY, Liu Y, Zhang JW, Ge GB, Liu HX, Wang LM, et al. C-7 con-fgura tion as one of determinants in taxanes metabolism by human cyto chrome P450 enzymes. Xenobiotica 2009; 39: 903-14
19. Liang SC, Ge GB, Liu HX, Zhang YY, Wang LM, Zhang JW, et al. dentifcation and characterization of human udp-glucurono syltrans-ferases responsible for the in vitro glucuronidation of daphnetin. Drug Metab Dispos 2010; 38: 973-80
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75
21. Liu Y, Ma H, Zhang JW, Deng MC, Yang L. Infuence of ginsenoside Rh-1 and F-1 on human cytochrome P450 enzymes. Planta Med 2006; 72: 126-31. (Pubitemid 43293866)
22. Zhang JW, Liu Y, Li W, Hao DC, Yang L Inhibitory effect of medroxy pro-ges ter one acetate on human liver cytochrome P450 enzymes. Eur J Clin Pharmacol 2006; 62: 497-502
23. Dong PP, Ge GB, Zhang YY, Ai CZ, Li GH, Zhu LL, et al. Quantitative structure-retention relationship studies for taxanes including epimers and isomeric metabolites in ultra fast liquid chromatography. J Chromatogr A 2009; 1216: 7055-62
24. Liu YT, Hao K, Liu XQ, Wang GJ. Metabolism and metabolic inhibition of gambogic acid in rat liver microsomes. Acta Pharmacol Sin 2006; 27: 1253-58 (Pubitemid 44411008)
25. Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L. Time-dependent nhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmaco 2010; 69: 193-9.
26. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA Rettie AE, et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998; 37: 4137-47 (Pubitemid 28166435)
27. Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based nactiva tion of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007; 35: 246-55 (Pubitemid 46148737)
28. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The infuence of nonspecifc microsomal binding on apparent intrinsic clearance and its prediction from physicochemical properties. Drug Metab Dispos 2002; 30: 1497-503 (Pubitemid 35397059)
29. Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating paralle pathways of drug elimination and inhibitor absorption rate constant Br J Clin Pharmacol 2005; 60: 508-18 (Pubitemid 41532451)
30. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, et al. Comparison of different algorithms for predicting clinical drug-drug nteractions, based on the use of cyp3a4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 2009 37: 1658-66
31. Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T Yamada Y, et al. Phase I dose-fnding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2008; 61: 489-96 (Pubitemid 350275984)
32. Hutzler JM, Kolwankar D, Hummel MA, Tracy TS. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs Kinetics and structural requirements. Drug Metab Dispos 2002; 30 1194-200 (Pubitemid 35265825)
33. Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev 2002; 34: 83-448 (Pubitemid 34311090)
34. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35: 692-706
35. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AYH. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-depend ent. Drug Metab Dispos 2000; 28: 360-6 (Pubitemid 30137063)
36. Schwab GE, Raucy JL, Johnson EF. Modulation of rabbit and human hepatic cytochrome-p-450-catalyzed steroid hydroxylations by alpha-naphthofavone. Mol Pharmacol 1988; 33: 493-9
37. Yun CH, Wood M, Wood AJJ, Guengerich FP. Identification of the pharmacogenetic determinants of alfentanil metabolism-cytochrome p-450-3a4\an explanation of the variable elimination clearance Anesthesiology 1992; 77: 467-74
38. Hao M, Zhao YQ, Chen PZ, Huang H, Liu H, Jiang HL, et al. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing p450 enzymes. PLoS One 2008; 3: e2697
39. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004; 305: 683-6 (Pubitemid 39006760)
40. Tracy TS. Atypical enzyme kinetics: Their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. Curr Drug Metab 2003; 4: 341-6. (Pubitemid 37279359)
41. Nomeir AA, Ruegg C, Shoemaker M, Favreau LV, Palamanda JR Silber P, et al. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Dispos 2001; 29: 748-53 (Pubitemid 32374578)
42. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KHJ, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutica research and manufacturers of america. Drug Metab Dispos 2009; 37: 1355-70
43. Henshall J, Galetin A, Harrison A, Houston JB. Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications. Drug Metab Dispos 2008; 36: 1332-40 (Pubitemid 351929318)
44. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Com-pari son of K-I values and impact of CYP3A5 expression. Drug Metab Dispos 1999; 27: 180-7. (Pubitemid 29072069)
45. McConn DJ, Lin YS, Allen K, Kunze KL, Thummel KE. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-nhibitor complex-forming drugs. Drug Metab Dispos 2004; 32 1083-91. (Pubitemid 39287581)
46. Li XH, Kamenecka TM, Cameron MD. Cytochrome P450-mediated bio activation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 2010; 38: 1238-45
47. Li X, Kamenecka TM, Cameron MD. Bioactivation of the epiderma growth factor receptor inhibitor geftinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol 2009; 22: 1736-42
48. Li XH, He YJ, Ruiz CH, Koenig M, Cameron MD. Characterization of dasatinib and its structural analogs as cyp3a4 mechanism-based nactivators and the proposed bioactivation pathways. Drug Metab Dispos 2009; 37: 1242-50